DE60110219T2 - Adenosin a2a rezeptor antagonisten - Google Patents

Adenosin a2a rezeptor antagonisten Download PDF

Info

Publication number
DE60110219T2
DE60110219T2 DE60110219T DE60110219T DE60110219T2 DE 60110219 T2 DE60110219 T2 DE 60110219T2 DE 60110219 T DE60110219 T DE 60110219T DE 60110219 T DE60110219 T DE 60110219T DE 60110219 T2 DE60110219 T2 DE 60110219T2
Authority
DE
Germany
Prior art keywords
alkyl
alkoxy
formula
mmol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60110219T
Other languages
German (de)
English (en)
Other versions
DE60110219D1 (de
Inventor
R. Bernard NEUSTADT
A. Neil LINDO
J. William GREENLEE
Deen Tulshian
S. Lisa SILVERMAN
Yan Xia
D. Craig BOYLE
Samuel Chackalamannil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE60110219D1 publication Critical patent/DE60110219D1/de
Application granted granted Critical
Publication of DE60110219T2 publication Critical patent/DE60110219T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60110219T 2000-05-26 2001-05-24 Adenosin a2a rezeptor antagonisten Expired - Lifetime DE60110219T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20714300P 2000-05-26 2000-05-26
US207143P 2000-05-26
PCT/US2001/016954 WO2001092264A1 (en) 2000-05-26 2001-05-24 Adenosine a2a receptor antagonists

Publications (2)

Publication Number Publication Date
DE60110219D1 DE60110219D1 (de) 2005-05-25
DE60110219T2 true DE60110219T2 (de) 2006-03-09

Family

ID=22769372

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60110219T Expired - Lifetime DE60110219T2 (de) 2000-05-26 2001-05-24 Adenosin a2a rezeptor antagonisten

Country Status (31)

Country Link
US (4) US6630475B2 (enExample)
EP (1) EP1283839B1 (enExample)
JP (3) JP4574112B2 (enExample)
KR (1) KR100520907B1 (enExample)
CN (2) CN100384847C (enExample)
AR (1) AR028621A1 (enExample)
AT (1) ATE293627T1 (enExample)
AU (2) AU6808901A (enExample)
BR (1) BRPI0111015B8 (enExample)
CA (1) CA2410237C (enExample)
CZ (1) CZ303790B6 (enExample)
DE (1) DE60110219T2 (enExample)
DK (1) DK1283839T3 (enExample)
EC (1) ECSP024364A (enExample)
ES (1) ES2237576T3 (enExample)
HK (1) HK1049007B (enExample)
HU (1) HU230420B1 (enExample)
IL (3) IL152726A0 (enExample)
MX (1) MXPA02011625A (enExample)
MY (1) MY132006A (enExample)
NO (1) NO325008B1 (enExample)
NZ (1) NZ522326A (enExample)
PE (1) PE20020062A1 (enExample)
PL (1) PL218764B1 (enExample)
PT (1) PT1283839E (enExample)
RU (1) RU2315053C2 (enExample)
SI (1) SI1283839T1 (enExample)
SK (1) SK287748B6 (enExample)
TW (1) TWI288137B (enExample)
WO (1) WO2001092264A1 (enExample)
ZA (1) ZA200208898B (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2315053C2 (ru) * 2000-05-26 2008-01-20 Шеринг Корпорейшн ПРОИЗВОДНЫЕ 5-АМИНО-ПИРАЗОЛО-[4,3-е]-1,2,4-ТРИАЗОЛО[1,5-с]ПИРИМИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ПРИМЕНЕНИЕ И СПОСОБЫ ПОЛУЧЕНИЯ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
US20030139395A1 (en) * 2001-09-13 2003-07-24 Schering Corporation Combination of an adenosine A2a receptor antagonist and an antidepressant or anxiolytic
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2003048165A1 (en) * 2001-11-30 2003-06-12 Schering Corporation ADENOSINE A2a RECEPTOR ANTAGONISTS
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
KR20050044600A (ko) 2001-11-30 2005-05-12 쉐링 코포레이션 [1,2,4]-트리아졸 바이사이클릭 아데노신 Ａ2ａ 수용체길항제
TR201903603T4 (tr) 2002-01-28 2019-04-22 Kyowa Hakko Kogyo Kk Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri.
MXPA04000908A (es) * 2002-05-30 2004-03-26 King Pharmaceuticals Res & Dev Compuestos farmaceuticamente activos que tienen estructura de anillo de pirazolotriazolopirimidina triciclica y metodos de uso.
JP2006514697A (ja) * 2002-12-19 2006-05-11 シェーリング　コーポレイション アデノシンＡ２ａレセプターアンタゴニストの使用
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
WO2004092172A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
NZ542823A (en) * 2003-04-23 2009-03-31 Schering Corp 2-Alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
CA2528710C (en) * 2003-06-10 2012-04-17 Kyowa Hakko Kogyo Co., Ltd. A method of treating an anxiety disorder
EP1636187A1 (en) * 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
AU2004283751B2 (en) * 2003-10-24 2011-05-19 Exelixis, Inc. p70S6 kinase modulators and method of use
DK1678182T3 (da) 2003-10-28 2007-06-04 Schering Corp Fremgangsmåde til fremstilling af substituerede 5-amino-pyrazolo[4,3-E]-1,2,4-triazolo-[1,5-C]pyrimidiner
ATE377599T1 (de) * 2003-12-01 2007-11-15 Schering Corp Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen
CN100528162C (zh) * 2003-12-19 2009-08-19 先灵公司 药物组合物
ES2342082T3 (es) 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
WO2006132275A1 (ja) * 2005-06-07 2006-12-14 Kyowa Hakko Kogyo Co., Ltd. 運動障害の予防および／または治療剤
WO2007035542A1 (en) 2005-09-19 2007-03-29 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
AR056080A1 (es) * 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
TW200840566A (en) * 2006-12-22 2008-10-16 Esteve Labor Dr Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
WO2009110955A2 (en) * 2008-02-29 2009-09-11 Albert Einstein College Of Medicine Of Yeshiva University Ketoconazole-derivative antagonists of human pregnane x receptor and uses thereof
EP2262811B1 (en) 2008-03-04 2016-04-27 Merck Sharp & Dohme Corp. 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
EP2274007B1 (en) 2008-03-10 2016-12-14 Cornell University Modulation of blood brain barrier permeability
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
BRPI0916203A2 (pt) * 2008-07-23 2018-05-15 Kyowa Hakko Kirin Co Ltd agente terapêutico e/ou preventivo para enxaqueca, método para tratar e/ou prevenir enxaqueca, e, uso de um composto
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2010078430A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
EP2389175A1 (en) 2009-01-20 2011-11-30 Schering Corporation Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
AU2010232727A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted heterocyclic compounds
WO2010147941A1 (en) 2009-06-15 2010-12-23 Marvell World Trade Ltd. System and methods for gamut bounded saturation adaptive color enhancement
EP2462144B1 (en) 2009-08-07 2017-09-20 Merck Sharp & Dohme Corp. PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
RU2602814C2 (ru) 2009-09-25 2016-11-20 Оризон Дженомикс С.А. Лизинспецифические ингибиторы деметилазы-1 и их применение
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
MX2012012111A (es) 2010-04-19 2013-05-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especifica de lisina y su uso.
CA2806008C (en) 2010-07-29 2019-07-09 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
JP5843869B2 (ja) * 2010-09-24 2016-01-13 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
WO2012129381A1 (en) * 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2013024474A1 (en) * 2011-08-18 2013-02-21 Mapi Phrarma Ltd. Polymorphs of preladenant
CN103958474B (zh) 2011-10-20 2017-03-08 奥莱松基因组股份有限公司 作为lsd1抑制剂的(杂)芳基环丙基胺化合物
CN107266345B (zh) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
WO2014071512A1 (en) * 2012-11-06 2014-05-15 Universite Laval Combination therapy and methods for the treatment of respiratory diseases
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
BR112017010261A2 (pt) 2014-11-18 2018-02-06 Merck Sharp & Dohme Corp. composto, composição farmacêutica, e, método de tratamento para tratar distúrbios do sistema nervoso central (cns).
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
EP3307067B1 (en) 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
WO2018178338A1 (en) * 2017-03-30 2018-10-04 Iteos Therapeutics 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
CN110678472B (zh) * 2017-03-30 2023-01-24 伊忒欧斯比利时股份公司 作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
WO2019135259A1 (en) * 2018-01-04 2019-07-11 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
KR20200139153A (ko) 2018-02-27 2020-12-11 인사이트 코포레이션 A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
CN108276345A (zh) * 2018-03-22 2018-07-13 重庆奥舍生物化工有限公司 一种药物中间体嘧啶-5-甲醛的制备方法
CA3095839A1 (en) * 2018-04-08 2019-10-17 Beigene, Ltd. Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
CA3105721A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
TW202039496A (zh) 2018-11-30 2020-11-01 美商默沙東藥廠 做為腺苷受體拮抗劑之9-經取代胺基三唑喹唑啉衍生物、醫藥組合物及其用途
TW202504901A (zh) 2018-12-20 2025-02-01 美商英塞特公司 咪唑并嗒嗪及咪唑并吡啶化合物及其用途
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020227156A1 (en) * 2019-05-03 2020-11-12 Nektar Therapeutics Adenosine 2 receptor antagonists
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
WO2021011670A1 (en) * 2019-07-17 2021-01-21 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists and uses thereof
CN111825698B (zh) 2019-07-30 2021-10-15 杭州阿诺生物医药科技有限公司 腺苷受体拮抗剂
CN112479956A (zh) 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
CN111072675A (zh) * 2019-12-12 2020-04-28 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法
CN118812539B (zh) * 2024-06-19 2025-11-28 苏州大学 一种5-氨基三唑并嘧啶衍生物及其制备方法
CN118812544A (zh) * 2024-06-19 2024-10-22 厦门大学 一种腺苷a2ar靶向小分子化合物、核素标记探针及其制备方法、应用和药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217748B1 (en) 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
SU1739850A3 (ru) * 1987-08-31 1992-06-07 Такеда Кемикал Индастриз, Лтд (Фирма) Способ получени конденсированных производных пиразоло[3,4- @ ]пиримидина
IT1264901B1 (it) * 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) * 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
RU2315053C2 (ru) * 2000-05-26 2008-01-20 Шеринг Корпорейшн ПРОИЗВОДНЫЕ 5-АМИНО-ПИРАЗОЛО-[4,3-е]-1,2,4-ТРИАЗОЛО[1,5-с]ПИРИМИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ПРИМЕНЕНИЕ И СПОСОБЫ ПОЛУЧЕНИЯ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
WO2003048165A1 (en) * 2001-11-30 2003-06-12 Schering Corporation ADENOSINE A2a RECEPTOR ANTAGONISTS
JP2006514697A (ja) * 2002-12-19 2006-05-11 シェーリング　コーポレイション アデノシンＡ２ａレセプターアンタゴニストの使用
DK1678182T3 (da) * 2003-10-28 2007-06-04 Schering Corp Fremgangsmåde til fremstilling af substituerede 5-amino-pyrazolo[4,3-E]-1,2,4-triazolo-[1,5-C]pyrimidiner
ATE377599T1 (de) * 2003-12-01 2007-11-15 Schering Corp Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen
ES2342082T3 (es) * 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
WO2007035542A1 (en) * 2005-09-19 2007-03-29 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
ZA200208898B (en) 2004-03-01
HUP0600239A3 (en) 2008-06-30
PL360472A1 (en) 2004-09-06
TWI288137B (en) 2007-10-11
NZ522326A (en) 2006-03-31
CN100384847C (zh) 2008-04-30
IL220174A (en) 2015-07-30
CN1451007A (zh) 2003-10-22
JP2007145875A (ja) 2007-06-14
JP2003535094A (ja) 2003-11-25
PT1283839E (pt) 2005-08-31
CA2410237C (en) 2008-01-08
CZ20023886A3 (cs) 2003-02-12
CN1247588C (zh) 2006-03-29
BRPI0111015B1 (pt) 2017-11-07
HK1049007A1 (en) 2003-04-25
DE60110219D1 (de) 2005-05-25
CN1800186A (zh) 2006-07-12
AU6808901A (en) 2001-12-11
EP1283839A1 (en) 2003-02-19
HK1049007B (en) 2005-09-16
NO20025651D0 (no) 2002-11-25
IL220174A0 (en) 2012-07-31
MY132006A (en) 2007-09-28
ATE293627T1 (de) 2005-05-15
US7067655B2 (en) 2006-06-27
AU2001268089C1 (en) 2006-04-13
US6897216B2 (en) 2005-05-24
MXPA02011625A (es) 2003-03-27
EP1283839B1 (en) 2005-04-20
USRE44205E1 (en) 2013-05-07
IL152726A (en) 2012-07-31
ES2237576T3 (es) 2005-08-01
JP4938348B2 (ja) 2012-05-23
BR0111015A (pt) 2005-01-11
AR028621A1 (es) 2003-05-14
PL218764B1 (pl) 2015-01-30
CA2410237A1 (en) 2001-12-06
KR20030003746A (ko) 2003-01-10
HU230420B1 (hu) 2016-05-30
HUP0600239A2 (en) 2006-07-28
US20040023997A1 (en) 2004-02-05
RU2315053C2 (ru) 2008-01-20
US20020099061A1 (en) 2002-07-25
PE20020062A1 (es) 2002-02-02
US20050026932A1 (en) 2005-02-03
CZ303790B6 (cs) 2013-05-09
WO2001092264A1 (en) 2001-12-06
SI1283839T1 (enExample) 2005-08-31
NO20025651L (no) 2003-01-23
JP2006219497A (ja) 2006-08-24
SK16712002A3 (sk) 2003-08-05
DK1283839T3 (da) 2005-07-25
SK287748B6 (sk) 2011-08-04
US6630475B2 (en) 2003-10-07
IL152726A0 (en) 2003-06-24
KR100520907B1 (ko) 2005-10-11
AU2001268089B2 (en) 2005-04-28
JP4574112B2 (ja) 2010-11-04
BRPI0111015B8 (pt) 2021-05-25
NO325008B1 (no) 2008-01-14
ECSP024364A (es) 2003-03-31

Similar Documents

Publication Publication Date Title
DE60110219T2 (de) Adenosin a2a rezeptor antagonisten
DE60219196T2 (de) BICYCLISCHE [1,2,4]-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
DE60209251T2 (de) Adenosine a2a receptor antagonisten
EP0944631B1 (de) Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen
AU2001268089A1 (en) Adenosine A2a receptor antagonists
EP1448565B1 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
DE69632032T2 (de) Gefässverschliessende substituierte 2,3- dihydro -1,4- dioxinopyridine
HK1063780B (en) Adenosine a2a receptor antagonists
HK1064100B (en) Adenosine a 2a receptor antagonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition